Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright

H.C. Wainwright reiterates a Buy rating on Rein Therapeutics (RNTX) with a $10 price target after the company said it dosed the first patient in its Phase 2 clinical trial evaluating LTI-03 for idiopathic pulmonary fibrosis. The story is now shifting toward clinical execution, the analyst tells investors in a research note. The firm says the regulatory uncertainty is now largely behind the program. Rein’s risk/reward is positive as investor focus turns to whether LTI-03’s early biomarker signals translate into a clinically meaningful efficacy signal, contends H.C. Wainwright.